Antenatal steroid treatment prevents severe hyperkalemia in very low-birthweight infants

Naoki Uga1, Yuko Nemoto, Tetsuya Ishii

  • 1Division of Neonatology, Perinatal Center, Toho University School of Medicine, Otaku, Tokyo, Japan. naokiuga@med.toho-u.ac.jp

Insights

Antenatal steroid treatment significantly lowers serum potassium in very low-birthweight (VLBW) infants, reducing cardiac arrhythmia and the need for glucose-insulin therapy. This finding aids in managing hyperkalemia in premature infants.

Area of Science:

  • Neonatal Medicine
  • Pediatric Cardiology
  • Biochemistry

Background:

  • Hyperkalemia is a common and potentially dangerous condition in very low-birthweight (VLBW) infants, sometimes leading to cardiac arrhythmias.
  • Identifying factors that contribute to elevated serum potassium levels in this vulnerable population is crucial for effective management.

Purpose of the Study:

  • To investigate the impact of antenatal steroid treatment on serum potassium concentrations in VLBW infants.
  • To identify risk factors associated with severe hyperkalemia in VLBW infants.

Main Methods:

  • A retrospective comparative analysis of 140 VLBW infants requiring mechanical ventilation.
  • Comparison of serum potassium levels at 24 and 48 hours of age between infants whose mothers received antenatal steroids and those who did not.
  • Risk factor analysis for severe hyperkalemia using multiple linear regression and Pearson's partial correlation.

Main Results:

  • Antenatal steroid treatment significantly reduced serum potassium concentrations at 24 and 48 hours.
  • The incidence of cardiac arrhythmia and the need for glucose-insulin treatment for hyperkalemia were lower in infants exposed to antenatal steroids.
  • Serum potassium levels were associated with antenatal steroid treatment, fluid intake, serum sodium, gestational age, and blood urea nitrogen, but not urine output or serum creatinine.

Conclusions:

  • Antenatal steroid hormone treatment is effective in reducing early hyperkalemia in VLBW infants.
  • This treatment also decreases the incidence of cardiac arrhythmia and the requirement for glucose-insulin therapy in this population.
Abstract

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...